Alberto Fernandez-Tejada

This inventor holds 11 USPTO granted patents and 2 published patent applications, plus 1 CIPO patent and 1 EPO patent. Top assignees: Memorial Sloan Kettering Cancer Center, Sloan-Kettering Institute for Cancer Research, Adjuvance Technologies, Inc.. Active years: 2017-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Alberto Fernandez-Tejada. Retrieved from https://idiyas.com/inventor/alberto-fernandez-tejada

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 11 (Patent Applications = 2)

% Patents Active = 90.9

CIPO Patents = 1

EPO Patents = 1 (Patent Applications = 3)

Average Co-Inventor Count = 6.0

ph-index = 2

Forward Citations = 20(Granted Patents)

Location History:

New York City, NY (US) (2020)
Logrono, ES (2021)
Logroño. la Rioja, ES (2021)
New York, NY (US) (2017 - 2023)

Company Filing History:

9 out of 621

Memorial Sloan Kettering Cancer Center

patents

2 out of 519

Sloan-Kettering Institute for Cancer Research

patents

1 out of 6

Adjuvance Technologies, Inc.

patents

where one patent can have more than one assignee

Years Active: 2017-2026

Loading Chart...

11 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12698304 - Triterpene saponin variants, methods of synthesis and use thereof (2026-08-04),

2. 12466894 - ANTI-MUC16 ANTIBODIES AND USES THEREOF (2025-11-11),

3. 12227535 - Triterpene saponins, methods of synthesis and uses thereof (2025-02-18),

4. 12187755 - Minimal saponin analogues, synthesis and use thereof (2025-01-07),

5. 11629162 - Triterpene saponin variants, methods of synthesis and use thereof (2023-04-18),

6. 11447515 - Triterpene saponins, methods of synthesis and uses thereof (2022-09-20),

7. 11274116 - Minimal saponin analogues, synthesis and use thereof (2022-03-15),

8. 11066480 - Anti-MUC16 antibodies and uses thereof (2021-07-20),

9. 10906926 - Triterpene saponin analogues (2021-02-02),

10. 10626137 - Minimal saponin analogues, synthesis and use thereof (2020-04-21),

11. 9718850 - Triterpene saponins, methods of synthesis and uses thereof (2017-08-01),

Title: Innovations of Alberto Fernandez-Tejada

Introduction

Alberto Fernandez-Tejada is a prominent inventor based in New York, NY (US), known for his significant contributions to the field of immunology and vaccine development. With a total of nine patents to his name, he has made remarkable strides in the synthesis and application of triterpene saponins.

Latest Patents

Among his latest patents, the invention titled "Triterpene saponins, methods of synthesis and uses thereof" stands out. This invention relates to triterpene glycoside saponin-derived adjuvants, including the synthesis of QS-7, a potent immuno-adjuvant that is significantly less toxic than QS-21. The novel semi-synthetic method provided in this patent facilitates the synthesis of QS-7 and QS-21 analogs, which are crucial for preclinical and clinical evaluations. Another notable patent is "Minimal saponin analogues, synthesis and use thereof," which discloses truncated triterpene saponin analogues and their pharmaceutical compositions. This patent also outlines methods for immunizing subjects using these minimal saponin analogues.

Career Highlights

Alberto has had a distinguished career, working at prestigious institutions such as Memorial Sloan Kettering Cancer Center and the Sloan Kettering Institute for Cancer Research. His work has focused on advancing the understanding and application of

Profile summary based on public USPTO records.